Fig. 3: YAP Nanobody-bioPROTAC fusions induce intracellular YAP degradation and suppress tumor cell growth.
From: Targeted degradation of endogenous YAP by nanobody bioPROTAC inhibits tumor progression
Time-course experiments determining the degradation of YAP in uveal melanoma cells (OMM2.3 and 92.1) (A) gastric cancer cells (IM95 and AGS) (B) breast cancer cells (MDA-MB-231) (C) mesothelioma cells (NCI-H2373, NCI-H2052 and MSTO-211H) (D) following inducible expression of C3 or E8 nanobody-2RNF4 upon doxycycline (DOX) treatment (200 ng/ml). Quantification data are presented as mean ± SEM from three independent experiments. Colony formation assays validating the growth inhibitory effects of E8-2RNF4 on OMM2.3, 92.1 (E), IM95, AGS (F), MDA-MB-231 (G), NCI-H2373, NCI-H2052, MSTO-211H (H) cells (n = 3 biological replicates, mean ± SEM, two-sided Student’s t-test). I Cell apoptosis analysis by flow cytometry after staining with Annexin V-FITC and PI. Cells stably expressing inducible E8-2RNF4 or C3-2RNF4 were treated with DOX (200 ng/ml) for 48 h (n = 3 biological replicates, mean ± SEM, two-sided Student’s t-test, “ns” represents no significant difference). Amino acid sequences of E8-2RNF4 and C3-2RNF4 are available in Supplementary Note 1. Source data are provided as a Source Data file.
